Amphastar Pharmaceuticals (AMPH) EV to CFO (2014 - 2026)

Amphastar Pharmaceuticals has reported EV to CFO for 13 years, with the latest figure at 11.07 in Q2 2026.

• On a quarterly basis, EV to CFO fell 52.85% year-over-year to 11.07 in Q2 2026; TTM through Jun 2026 was 3.08, a 41.2% decrease from a year earlier, with the FY2025 full-year figure at 6.02, down 16.95% from the prior year.
• EV to CFO was 11.07 for Q2 2026 at Amphastar Pharmaceuticals, down from 12.18 in the prior quarter.
• The five-year high for EV to CFO was 540.34 in Q2 2022, with the low at 11.07 in Q2 2026.
• Average EV to CFO over 5 years is 67.27, with a median of 33.1 recorded in 2025.
• The sharpest annual moves came in 2022 and 2023: EV to CFO jumped 1856.96% in 2022, then plunged 91.1% in 2023.
• Over 5 years, EV to CFO stood at 77.0 in 2022, then surged by 47.83% to 113.82 in 2023, then sank by 53.19% to 53.28 in 2024, then sank by 46.34% to 28.59 in 2025, then sank by 61.28% to 11.07 in 2026.
• The last three EV to CFO figures came in at 11.07 (Q2 2026), 12.18 (Q1 2026), and 28.59 (Q4 2025), per Business Quant data.